RU2019101864A - Фармацевтическая композиция для лечения недержания мочи и способ ее применения - Google Patents

Фармацевтическая композиция для лечения недержания мочи и способ ее применения Download PDF

Info

Publication number
RU2019101864A
RU2019101864A RU2019101864A RU2019101864A RU2019101864A RU 2019101864 A RU2019101864 A RU 2019101864A RU 2019101864 A RU2019101864 A RU 2019101864A RU 2019101864 A RU2019101864 A RU 2019101864A RU 2019101864 A RU2019101864 A RU 2019101864A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
acetaminophen
amount
specified
treatment
Prior art date
Application number
RU2019101864A
Other languages
English (en)
Russian (ru)
Inventor
Дэвид А. ДИЛЛ
Original Assignee
УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/560,665 external-priority patent/US8445011B2/en
Priority claimed from US13/800,761 external-priority patent/US20130196012A1/en
Priority claimed from US13/847,940 external-priority patent/US8703184B2/en
Application filed by УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи filed Critical УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Publication of RU2019101864A publication Critical patent/RU2019101864A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2019101864A 2012-07-27 2013-06-28 Фармацевтическая композиция для лечения недержания мочи и способ ее применения RU2019101864A (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13/560,665 US8445011B2 (en) 2010-07-08 2012-07-27 Delayed-release formulation for reducing the frequency of urination and method of use thereof
US13/560,665 2012-07-27
US13/800,761 2013-03-13
US13/800,761 US20130196012A1 (en) 2010-11-30 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/847,940 US8703184B2 (en) 2010-07-08 2013-03-20 Delayed-release formulation for reducing the frequency of urination and method of use thereof
US13/847,940 2013-03-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015106762A Division RU2015106762A (ru) 2012-07-27 2013-06-28 Фармацевтическая композиция для лечения недержания мочи и способ ее применения

Publications (1)

Publication Number Publication Date
RU2019101864A true RU2019101864A (ru) 2019-03-11

Family

ID=49997724

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2019101864A RU2019101864A (ru) 2012-07-27 2013-06-28 Фармацевтическая композиция для лечения недержания мочи и способ ее применения
RU2015106762A RU2015106762A (ru) 2012-07-27 2013-06-28 Фармацевтическая композиция для лечения недержания мочи и способ ее применения
RU2015106672A RU2015106672A (ru) 2012-07-27 2013-06-28 Фармацевтическая композиция для уменьшения частоты мочеиспускания и способ ее применения

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU2015106762A RU2015106762A (ru) 2012-07-27 2013-06-28 Фармацевтическая композиция для лечения недержания мочи и способ ее применения
RU2015106672A RU2015106672A (ru) 2012-07-27 2013-06-28 Фармацевтическая композиция для уменьшения частоты мочеиспускания и способ ее применения

Country Status (16)

Country Link
US (3) US20160022615A1 (OSRAM)
EP (3) EP2877179A4 (OSRAM)
JP (4) JP2015522658A (OSRAM)
KR (2) KR20150048740A (OSRAM)
CN (4) CN107661326A (OSRAM)
AU (3) AU2013293489B2 (OSRAM)
BR (2) BR112015001627A2 (OSRAM)
CA (2) CA2875818A1 (OSRAM)
HK (4) HK1205931A1 (OSRAM)
IL (3) IL236028A0 (OSRAM)
MX (2) MX2015001188A (OSRAM)
MY (1) MY171526A (OSRAM)
RU (3) RU2019101864A (OSRAM)
SG (2) SG11201500578VA (OSRAM)
WO (2) WO2014018222A1 (OSRAM)
ZA (2) ZA201408993B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12370144B2 (en) 2021-02-23 2025-07-29 Otsuka Pharmaceutical Co., Ltd. Centanafadine pharmaceutical formulations, and methods of making and using same

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016317092A1 (en) * 2015-09-01 2018-04-26 Wellesley Pharmaceuticals, Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof
WO2017058428A1 (en) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
SG11201805527QA (en) * 2015-09-30 2018-07-30 Wellesley Pharmaceuticals Llc Composition for reducing the frequency of urination, method of making and use thereof
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
MX2019004191A (es) * 2017-11-07 2020-02-12 Poviva Tea Llc Composiciones de alimentos y bebidas que comprenden inhibidores de pde5.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE306250T1 (de) * 1998-12-23 2005-10-15 Alza Corp Dosierungsformen, die poröse partikel enthalten
AU7360700A (en) * 1999-09-09 2001-04-10 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
BR0113644A (pt) * 2000-08-30 2003-07-29 Lilly Icos Llc Usos do inibidor de pde5 no tratamento de enxaqueca
WO2003029199A1 (en) * 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Benzene derivatives, process for preparing the same and use thereof
WO2003070233A1 (en) * 2002-02-19 2003-08-28 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
US7754767B2 (en) * 2002-11-06 2010-07-13 Trinity Laboratories, Inc. Method for treatment of premature ejaculation in humans
US20080009538A1 (en) * 2005-03-21 2008-01-10 Phil Skolnick Methods and compositions for the treatment of urinary incontinence
EP1741444A1 (en) * 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2007083323A2 (en) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
WO2007113243A2 (en) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
US8399410B2 (en) * 2007-08-06 2013-03-19 Allergan, Inc. Methods and devices for desmopressin drug delivery
CN101664555A (zh) * 2008-09-02 2010-03-10 许洁 用于治疗泌尿生殖系统感染性疾病的联合药物组合物
CN102028693A (zh) * 2009-09-30 2011-04-27 梁超峰 含有5-型磷酸二酯酶抑制剂的直肠给药组合物
US9260424B2 (en) * 2009-10-26 2016-02-16 Auspex Pharmaceuticals, Inc. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120141554A1 (en) * 2010-07-08 2012-06-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof
US8236857B2 (en) * 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US8236856B2 (en) * 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12370144B2 (en) 2021-02-23 2025-07-29 Otsuka Pharmaceutical Co., Ltd. Centanafadine pharmaceutical formulations, and methods of making and using same

Also Published As

Publication number Publication date
IL236622A0 (en) 2015-02-26
HK1250628A1 (zh) 2019-01-11
IL236028A0 (en) 2015-01-29
MY171526A (en) 2019-10-16
CA2875818A1 (en) 2014-01-30
CN107335057A (zh) 2017-11-10
KR20150048740A (ko) 2015-05-07
CN107661326A (zh) 2018-02-06
EP2844241A1 (en) 2015-03-11
JP2018127482A (ja) 2018-08-16
EP2844241A4 (en) 2015-04-29
JP2015522659A (ja) 2015-08-06
RU2015106762A (ru) 2016-09-20
HK1205932A1 (en) 2015-12-31
HK1246203A1 (zh) 2018-09-07
HK1205931A1 (en) 2015-12-31
RU2015106672A (ru) 2016-09-20
ZA201500459B (en) 2016-09-28
WO2014018223A1 (en) 2014-01-30
EP2877179A4 (en) 2016-03-02
BR112014031306A2 (pt) 2017-06-27
CN104470522A (zh) 2015-03-25
KR20150048741A (ko) 2015-05-07
AU2013293489A1 (en) 2015-03-12
MX2015001188A (es) 2015-05-07
SG11201500601QA (en) 2015-04-29
US20180344674A1 (en) 2018-12-06
AU2013293488B2 (en) 2018-05-17
JP2018039831A (ja) 2018-03-15
IL261232A (en) 2018-10-31
EP2877179A1 (en) 2015-06-03
SG11201500578VA (en) 2015-03-30
BR112015001627A2 (pt) 2017-07-04
ZA201408993B (en) 2016-09-28
CA2879640A1 (en) 2014-01-03
AU2013293488A2 (en) 2015-02-26
JP2015522658A (ja) 2015-08-06
US20160022615A1 (en) 2016-01-28
AU2013293488A1 (en) 2015-02-19
AU2018208765A1 (en) 2018-08-16
US20170100351A1 (en) 2017-04-13
WO2014018222A1 (en) 2014-01-30
EP3527204A1 (en) 2019-08-21
AU2013293489B2 (en) 2017-09-07
MX2015001190A (es) 2015-05-07
CN104540505A (zh) 2015-04-22

Similar Documents

Publication Publication Date Title
RU2019101864A (ru) Фармацевтическая композиция для лечения недержания мочи и способ ее применения
EA201790950A1 (ru) Способы и композиции, в частности, для лечения синдрома дефицита внимания
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
CL2007002867A1 (es) Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras.
CR10455A (es) Compuestos farmaceuticos
UA106457C2 (ru) Пероральная комплексная композиция, содержащая сложные эфиры жирной кислоты омега-3 и ингибитор hmg-coa редуктазы
IN2012DN01869A (OSRAM)
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
BR112014033055A8 (pt) Inibidores seletivos de delta pi3k
RU2015140572A (ru) Способы лечения колоректального рака
WO2010033977A3 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
PH12018500023A1 (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
WO2011133795A3 (en) Beta-carbolines as inhibitors of haspin and dyrk kinases
EP2629799A4 (en) TOPICAL BASE AND ACTIVE COMPOSITIONS AND PROCESS FOR THE CARE AND TREATMENT OF THE SKIN
EA200802324A1 (ru) Новая форма введения рацекадотрила
JP2013536238A5 (OSRAM)
WO2011149288A2 (ko) 복수의 타이로신 카이네이즈에 대한 저해 활성을 가지는 항염증 화합물 및 이를 포함하는 약학적 조성물
WO2008075231A3 (en) Diaper rash composition and method
MX351059B (es) Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.
UY29193A1 (es) Nuevas formulaciones de tabletas de liberación modificada para inhibidores de bomba de protón
CL2013000895A1 (es) Combinacion farmaceutica que comprende un compuesto derivado de imidazo[4,5-c]-quinolina, inhibidor de pik3/mtor, un compuesto alosterico inhibidor de mtor y opcionalmente un vehiculo farmaceuticamente aceptable; composicion farmaceutica; metodo para mejorar la eficacia del tratamiento; y su uso en una enfermedad proliferativa.
NZ714662A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
RU2016152226A (ru) Фармацевтический состав для уменьшения частоты мочеиспускания и способ его применения
JP2015522659A5 (OSRAM)
EA201390354A1 (ru) Хиноксалиновое соединение

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20160629